Low‐density lipoprotein (LDL) plays a key role in the development and progression of
atherosclerosis and cardiovascular disease. LDL consists of several subclasses of particles …

Lysophosphatidic acid (LPA) is a potent bioactive phospholipid. As many other biological
active lipids, LPA is an autacoid: it is formed locally on demand, and it acts locally near its …

Estrogen replacement therapy (ERT) is reported to lower the incidence of cardiovascular
disease in postmenopausal women. ERT also lowers the levels of oxidatively modified low …

Recent findings suggest that LDL (-) could contribute to atherogenesis via several
mechanisms, including proinflammatory, proapoptotic and antiangiogenesis properties …

Lipoproteins have been described as microRNAs (miRNAs) carriers. Unfortunately, the
bibliography on this topic is scarce and shows a high variability between independent …

Oxidative modifications in lipoproteins (LP), especially in low-density lipoproteins (LDL), are
associated with initiation and progression of atherosclerosis. The levels of a sub-fraction of …

Background—Electronegative LDL [LDL (−)], a modified subfraction of LDL present in
plasma, induces the release of interleukin-8 and monocyte chemotactic protein-1 from …

Background Type 2 diabetes mellitus (T2D) is associated with higher cardiovascular risk
partly related to an increase in inflammatory parameters. The aim of this study was to …

L5-LDL, the most electronegative LDL associated with major cardiovascular risks,
significantly rises in patients with ST-segment elevation myocardial infarction (STEMI). The …

Electronegative LDL (LDL (−)) constitutes a plasma subfraction of LDL with proinflammatory
properties. Its proportion is increased in familial hypercholesterolemia (FH); however, the …